Steering a Go/No-Go Decision for Clinical Development

Situation

A client with an early-stage bispecific antibody needed to make a go/no-go decision about moving forward with clinical development for patients with multiple myeloma.

Task

Articulate the unmet need and anticipated market evolution in multiple myeloma, outlining the essential attributes that a new therapy must have to win adoption in the treatment paradigm of the future.

Leveraged secondary intel to define the current treatment paradigm and proof-of-concept “bar” for therapies to date.

Used primary intel to validate key assumptions, pinpoint perceived strengths and weaknesses of current and emerging therapies and identify differentiation strategies of frontrunners in late-stage development.

Defined key attributes that a new entrant would need to possess to enter the future treatment paradigm in alignment with the evolution of unmet need.

Results

The client gained a clear, concise understanding of the challenges they would need to overcome to gain adoption with this type of bispecific in the multiple myeloma treatment paradigm. They made a no-go decision and devoted the time and resources saved into a different asset with a higher likelihood of success.

Gained understanding

Made a no-go decision

Chose a new asset

“The insights BTH delivered enabled us to have a productive conversation at our steering committee meeting and align on a no-go decision, in light the scope for differentiation and the timeline difference in terms of when we could hit the market. Mission accomplished! Feedback from the team was positive across the board.”

Director | Corporate Development

Discover Your Advantage

Learn how Brass Tacks Insights can accelerate your progress and bring clarity to your strategic initiatives.

Get Started

Steering a Go/No-Go Decision for Clinical Development

Situation

Task

Action

Results

Clarity Saved Time

and Resources

Discover Your Advantage